Introduction
HBV is a non-cytopathic, hepatotropic DNA virus that infects more than 300 million people world-wide, causing liver disease of variable severity (15). The pathogenesis of the liver damage during HBV infection is immune-mediated, and is dependent on the balance between viral replication and the CD8+ T cell response (7) . Virus-specific CD8+ cells are necessary for HBV control (25) but are defective in patients with persistent HBV infection when compared with those who resolved infection (11) . High antigen dose deletion (28) and lack of CD4 help (13) could explain the low number of virus-specific CD8+ cells present in patients with chronic infection. However, it remains possible that other direct mechanisms of regulation of CD8+ expansion operate in patients with chronic HBV infection, that still possess low frequencies of virus specific CD8+ cells in lymph nodes (18) , liver (17) and blood (28) . The suggestion that a residual population of cells is actively suppressed in chronic HBV infection is supported by the boosting of their frequencies on reduction of viral load with antiviral therapy (9) .
Studies in a large number of experimental models have provided convincing evidence that a population of specialised T cells able to actively regulate the immune response represents an integral part of the T cell repertoire (19, 21) . These cells have been shown to suppress immunological responses against self (3, 22) and foreign antigens (1, 6, 12, 24) and reside mainly, but not exclusively, within a minor subpopulation of CD4+ cells that express the phenotypic marker CD25 (4) . The mechanisms that mediate the regulatory effect of CD4+ CD25+ cells are still controversial, with evidence supporting regulation either through suppressive cytokines or direct cell-cell 4 contact (19) . CD4+ CD25+ regulatory cells develop in the thymus and are anergic to antigenic stimulation in vitro, but recent experiments have demonstrated their ability to expand in vivo following Ag recognition (27) . This ability of CD4+ CD25+ to respond to peripheral antigens could be particularly important in the regulation of immunopathological and protective responses to parasites (6) and viruses (1, 6, 12, 24) . In mice infected with HSV, CD4+ CD25+ cells were not only shown to regulate the clonal expansion of virus-specific CD8+ cells, but their suppressive function was also enhanced by the virus infection (24) . These data suggest that during viral infection, CD4+ CD25+ cells can be modulated in the periphery after recognition of viral antigens. Furthermore, recent data in HCV-infected subjects has shown the potential ability of CD4+ CD25+ to regulate HCV-specific T cells in patients with chronic hepatitis C (23) . These data raise the possibility that a dynamic regulation of virus-specific CD8+ responses can be mediated by CD4+ CD25+ during viral infection.
It is possible that CD4+ CD25+ cells are activated in vivo to suppress the expansion of the HBV-specific CD8+ cells able to escape deletion, thus precluding HBV clearance, but limiting excessive immune-mediated liver damage. To test this possibility, we explored the impact of circulating CD4+ CD25+ regulatory T cells in patients with chronic and resolved hepatitis B. We investigated whether in vivo 
Material and methods

Patients
Blood was collected with informed consent from 40 patients infected with HBV. The study was approved by the local ethics committee. Three subjects (R1, R2, R3) had clinical, biochemical and virological evidence of resolved acute hepatitis B infection (recovered from acute hepatitis B: normal ALT levels, anti-HBc+, HBsAg negative). Staining with HLA-tetrameric complexes. HLA-class I tetramers were purchased commercially (Proimmune, Oxford, UK). Tc18-27 is an HLA-A2 tetramer specific for HLA-A2 restricted core18-27 specific CD8 cells, T mel, is specific for HLA-A2 
Results and Discussion
CD4+ CD25+ cells in the circulation of HBeAg+ patients with chronic hepatitis B.
We tested the hypothesis that the inability to control viral replication and the absence showed a decrease of more than 1% (from 2.6% to 1.4%).
To investigate whether these decreases in circulating CD4+ CD25+ frequencies had any impact on HBV-specific CD8+ responsiveness, we analysed in parallel HBVspecific CD8 and CD4+ CD25+ frequency in two HLA-A2+ patients (Table I) HBV-DNA levels was < 10 5 copies/ml at all time points. 
